Table 1. Clinicopathological characteristics of the 16 patients with CRC.
| Case No. | Age | Sex* | Location | CRC size (cm) | Invasion depth^ | pN-factor | pStage at diagnosis | Adjuvant/Neoadjuvant chemotherapy # | Chemotherapy for metastasis# | 2nd chemotherapy# | Liver Metastasis Synchronous/ Metachronous with Primary |
Outcome (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C1 | 67 | F | Right side | 3.6 | SS | 2 | III | XELOX | XELOX | Metachronous | dead (37) | |
| C2 | 57 | F | Left side | 4.0 | SS | 2 | III | UFT+ LV | UFT+ LV | Metachronous | dead (56) | |
| C3 | 74 | M | Right side | 5.5 | SI | 2 | III | XELOX | XELOX | Metachronous | dead (27) | |
| C4 | 63 | F | Rectum | 8.0 | SE | 3 | ⋆IV | mFOLFOX6 | FOLFIRI | Metachronous | dead (28) | |
| C5 | 64 | M | Right side | 7.0 | SS | 2 | IV | XELOX+Bev | XELOX+Bev | Synchronous | alive (36) | |
| C6 | 78 | M | Rectum | 6.0 | SS | 1 | III | mFOLFOX6 | FOLFIRI | Metachronous | dead (42) | |
| C7 | 58 | F | Rectum | 3.0 | SS | 0 | II | None | mFOLFOX6 | FOLFIRI | Metachronous | dead (70) |
| C8 | 60 | M | Left side | 2.8 | MP | 0 | II | None | TS1 | Metachronous | alive (96) | |
| C9 | 69 | M | Rectum | 4.6 | SS | 0 | IV | None | mFOLFOX6+ Bev | Synchronous | alive (15) | |
| C10 | 47 | F | Right side | 6.0 | SE | 3 | IV | None | None | Synchronous | dead (5) | |
| C11 | 69 | M | Left side | 6.0 | SS | 0 | IV | None | XELOX+Bev | mFOLFOX6+ Bev | Synchronous | alive (37) |
| C12 | 52 | F | Rectum | 5.0 | SS | 3 | IV | None | mFOLFOX6 | Synchronous | alive (84) | |
| C13 | 41 | M | Rectum | 5.0 | A | 2 | IV | None | XELOX | IRIS+Bev | Synchronous | dead (31) |
| C14 | 73 | M | Right side | 7.0 | SS | 2 | IV | None | None | Synchronous | dead (71) | |
| C15 | 58 | M | Left side | 3.0 | SS | 1 | IV | None | UFT+ LV | Synchronous | alive (102) | |
| C16 | 72 | M | Left side | 4.8 | SS | 0 | IV | None | mFOLFOX6 | Synchronous | alive (12) |
*M–male; F–female ⋆para aortic lymph node metastasis
^SS–Tumor invades through the muscularis propria into pericolorectal tissue; SI–tumor directly invades or is adherent to other organs or structures;
SE–tumor penetrates to the surface of the visceral peritoneum; MP–tumor invades muscularis propria; A–rectal tumor invades through the muscularis propria into pericolorectal tissue
#XELOX–Capecitabine and oxaliplatin; UFT+ LV–uracil-tegafur plus leucovorin; mFOLFOX6–fluorouracil (5-FU) and leucovorin with oxaliplatin;
FOLFIRI–5-FU and leucovorin with irinotecan; Bev–bevacizumab; TS1–Oral fluoropyrimidine anticancer drug; IRIS–irinotecan and TS-1.